Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold R Collard

Showing results (171-180 of 213) with videos related to

Pageof 22
Sort By:
The Lancet. Respiratory Medicine|August 4, 2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trialsMargaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Plos One|July 1, 2016
miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary FibrosisSupparerk Disayabutr, Eun Kyung Kim, Seung-Ick Cha, et al.
Thorax|March 3, 2017
CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosisGuiquan Jia, Sanjay Chandriani, Alexander R Abbas, et al.
The European Respiratory Journal|April 23, 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trialsHarold R Collard, Williamson Z Bradford, Vincent Cottin, et al.
Respiratory Medicine|November 29, 2012
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosisJoyce S Lee, Eunice J Kim, Kara L Lynch, et al.
Thorax|June 2, 2016
A diagnostic model for chronic hypersensitivity pneumonitisKerri A Johannson, Brett M Elicker, Eric Vittinghoff, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b studySteven D Nathan, Jürgen Behr, Harold R Collard, et al.
Chest|June 21, 2017
Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL ModelJulie Morisset, Eric Vittinghoff, Brett M Elicker, et al.
Chest|March 5, 2014
A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung diseaseTracy J Doyle, Joyce S Lee, Paul F Dellaripa, et al.
Pageof 22

Showing results (171-180 of 213) with videos related to

Sort By:
Pageof 22
The Lancet. Respiratory Medicine|August 4, 2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trialsMargaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Plos One|July 1, 2016
miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary FibrosisSupparerk Disayabutr, Eun Kyung Kim, Seung-Ick Cha, et al.
Thorax|March 3, 2017
CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosisGuiquan Jia, Sanjay Chandriani, Alexander R Abbas, et al.
The European Respiratory Journal|April 23, 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trialsHarold R Collard, Williamson Z Bradford, Vincent Cottin, et al.
Respiratory Medicine|November 29, 2012
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosisJoyce S Lee, Eunice J Kim, Kara L Lynch, et al.
Thorax|June 2, 2016
A diagnostic model for chronic hypersensitivity pneumonitisKerri A Johannson, Brett M Elicker, Eric Vittinghoff, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b studySteven D Nathan, Jürgen Behr, Harold R Collard, et al.
Chest|June 21, 2017
Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL ModelJulie Morisset, Eric Vittinghoff, Brett M Elicker, et al.
Chest|March 5, 2014
A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung diseaseTracy J Doyle, Joyce S Lee, Paul F Dellaripa, et al.
Pageof 22